TRM-201 (Rofecoxib)

Phase 3Small molecule

TTremeau Pharmceuticals, Inc.

TRM-201 (Rofecoxib) is one of 14 small molecule programs targeting Arthropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthropathyActive, not recruiting

ArthropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Arthropathy

#DrugCompanyPhaseTrials

Marinol

Alnylam Pharmaceuticals

Enbrel

1 3

Cyklokapron

AAmring

Approved

—4

Naropin

FFresenius Kabi Oncology Ltd.

Approved

—5

Vancocin

HHikma Pharmaceuticals LLC

Prolia

1 7

Decadron

QQuince Therapeutics S.p.A.

Forteo

1 9

Botox

RRevance Therapeutics, Inc.

Phase 2

1 10

Cox-2 Inhibitor

SSeoul National University Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Arthropathy1 trial

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Terminated·TTremeau Pharmceuticals, Inc.·Phase 3·NCT04684511·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TRM-201 (Rofecoxib). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRM-201 (Rofecoxib) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRM-201 (Rofecoxib). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tremeau Pharmceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTremeau Pharmceuticals, Inc.

TRM-201 (Rofecoxib)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Arthropathy1 trial

References

Drug Info

Quick Facts

Related News